Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins

Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic's Recombinant Growth Factors and Media Proteins GlobeNewswire December 15, 2025 JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) — Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets today […]

PRGO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Perrigo Company plc Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

PRGO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Perrigo Company plc Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit GlobeNewswire December 15, 2025 SAN DIEGO, Dec. 15, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Perrigo

Inomin Expands Critical Minerals Discovery

Vancouver, British Columbia–(Newsfile Corp. – December 15, 2025) – Inomin Mines Inc. (TSXV: MINE) (“Inomin” or the “Company“) is pleased to report results from diamond drilling at the South zone of the 28,000 hectare Beaver-Lynx project in south-central, British Columbia, being explored in collaboration with Sumitomo Metal Mining Canada Ltd. The latest drilling results continue to

Ashcroft Capital Announces Acquisition of Birchstone Cedar Ridge

Class-A Community in the Dallas-Fort Worth Metroplex Features 360 Homes Ashcroft Capital, a fully integrated multifamily investment firm, today announced its acquisition of Birchstone Cedar Ridge, a luxury garden-style community in Dallas built in 2024. Ashcroft's affiliate property management arm, Birchstone Residential, is now providing services for the residents of the community.The acquisition was completed

First Phosphate cloture la troisieme tranche de son placement prive sursouscrit

CE COMMUNIQUÉ DE PRESSE N’EST PAS DESTINÉ À UNE DIFFUSION AUX ÉTAS-UNIS Saguenay, Québec–(Newsfile Corp. – 15 décembre 2025) – First Phosphate Corp. (CSE : PHOS) (OTCQX : FRSPF) (FSE : KD0) (« First Phosphate » ou la « Société ») a le plaisir d’annoncer que, le 12 décembre 2025, elle a clôturé la troisième tranche de

First Phosphate Closes Third Tranche of Oversubscribed Private Placement

THIS NEWS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES Saguenay, Quebec–(Newsfile Corp. – December 15, 2025) – First Phosphate Corp. (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) (“First Phosphate” or the “Company“) is pleased to announce that, on December 12, 2025, it closed the third tranche of its non-brokered private placement financing (the “Offering“), as further

HYPRLABS Emerges from Stealth with HYPRDRIVE™, A “No-Priors” AI Architecture Learning Directly from Reality

AI system learns continuously, runs light, delivering energy-efficient, domain-general autonomy for real-world robotics use cases HYPRLABS Inc. (HYPR), an AI robotics company based in San Francisco and Paris, today emerged from stealth with HYPRDRIVE™, a paradigm-shifting AI architecture designed to maximize Learning Velocity- the speed at which a robot turns exposure into intelligence. https://mma.prnewswire.com/media/2844653/HYPRLABS_Inc_Logo.jpg HYPRDRIVE™

Support for Parents with Infants at Pediatric Check-Ups Leads to Better Reading and Math Skills in Elementary School

Guiding parents to have pretend play and read aloud with their babies increased parental support of their children's cognitive development and academic skills by the time they turned six-especially for families facing poverty. https://mma.prnewswire.com/media/2329447/NYU_Langone_Health_Logo1.jpg This is the finding of a new study, led by researchers at NYU Grossman School of Medicine, New York University, and

Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

(NASDAQ:ZBIO),(HKSE:9969.HK),(Shenzhen:688428.SS), – Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE – – Zenas acquired the exclusive right to develop, manufacture and commercialize orelabrutinib in the field of Multiple Sclerosis globally, and non-oncology fields in all territories outside Greater China and Southeast Asia, in October

Kraig Biocraft Laboratories Successfully Completes Production Cycle, Delivering Over One Million BAM-1 Alpha Hybrid Eggs for Deployment

(Other OTC:KBLB),(OTC US:KBLB), ANN ARBOR, Mich., Dec. 15, 2025 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced the successful completion of its most recent production cycle, yielding more than one million BAM-1 Alpha hybrid eggs. These eggs are now staged for

Scroll to Top